VGYAAN Pharmaceuticals Receives US FDA Approval for Carbamazepine Tablets USP, 200 mg, Generic Equivalent to TEGRETOL®

August 16, 2021

Skillman, NJ -- VGYAAN Pharmaceuticals today announced that it has received final US FDA approval for Carbamazepine Tablets USP, 200 mg, the generic equivalent to TEGRETOL®.

Carbamazepine is indicated for patients with certain types of seizures (partial, generalized tonic-clonic, and mixed) and certain types of nerve pain (trigeminal and glossopharyngeal neuralgia).

"We are very excited to receive our fifth product approval by the FDA for Carbamazepine. This latest approval follows just one day after our fourth product approval by the FDA and really serves to showcase VGYAAN's robust capabilities and growing pipeline. I want to thank our very talented and hardworking team for achieving this significant milestone in our young company's journey, especially under these very challenging times during the pandemic this past year and a half. Our team is working diligently to launch Carbamazepine in the near future. In addition, we have multiple product applications with the FDA awaiting approvals in our quest to provide high quality, affordable generic drugs to patients," commented Nailesh Bhatt, Chief Executive Officer of VGYAAN Pharmaceuticals."

About VGYAAN Pharmaceuticals

VGYAAN Pharmaceuticals LLC, headquartered in Skillman, New Jersey is focused on developing and commercializing clinically critical drugs. VGYAAN is fully equipped and licensed to perform sales, marketing, and distribution of high quality and affordable drugs in the US with capabilities to serve clients across a wide range of channels. Our product portfolio includes solid orals and injectables in a broad range of therapeutic areas.

For more information, please visit www.vgyaan.com or contact media@vgyaan.com.